



## Clinical trial results:

**Double-blind, randomised clinical study comparing efficacy and safety of Clindamycin/Benzoyl Peroxide Gel (10 mg/g + 30 mg/g) (Test) vs. DUAC 10 mg/g + 30 mg/g Gel (Reference) vs. Vehicle in patients with papulopustular acne**

### Summary

EudraCT number	2017-000521-13
Trial protocol	CZ
Global end of trial date	01 March 2021

### Results information

Result version number	v1 (current)
This version publication date	09 April 2022
First version publication date	09 April 2022

### Trial information

#### Trial identification

Sponsor protocol code	17-01/ClinBPO-30
-----------------------	------------------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	Dermapharm AG
Sponsor organisation address	Lil-Dagover-Ring 7, Gruenwald, Germany, 82031
Public contact	Clinical Research Department, Dermapharm AG, +49 89641860, Clinicaltrials.Dermapharm@dermapharm.com
Scientific contact	Clinical Research Department, Dermapharm AG, +49 89641860, Clinicaltrials.Dermapharm@dermapharm.com

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	21 October 2021
Is this the analysis of the primary completion data?	Yes
Primary completion date	01 March 2021
Global end of trial reached?	Yes
Global end of trial date	01 March 2021
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

Evaluation of the efficacy and safety of a new gel containing 10 mg/g Clindamycin and 30 mg/g Benzoyl peroxide vs. DUAC 10 mg/g + 30 mg/g Gel (Reference) vs. vehicle in patients with papulopustular acne

Protection of trial subjects:

In the current clinical trial patients below the age of 18 have been included. In such a case, an age-appropriate written subject information sheet was handed over to adolescent patients and an appropriate information session was to be performed by the investigator. The legal guardian(s) received a comparable document and an information session for adults. Before the start of screening and randomisation for the current clinical trial, the legal guardian(s) had to sign the informed consent form(s) and the adolescent patient the informed assent form. In case any of the parties (legal guardian(s) or adolescent patient) refused their consent, a participation of the adolescent patient in the trial was not possible.

Background therapy:

There was no background therapy.

Evidence for comparator:

The comparator contains the same ingredients in the same concentration as the test product and has a marketing license for the study indication.

Actual start date of recruitment	03 April 2019
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Czechia: 676
Worldwide total number of subjects	676
EEA total number of subjects	676

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0

Children (2-11 years)	0
Adolescents (12-17 years)	378
Adults (18-64 years)	298
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

16 study centers in Czechia; first patient first visit: 25 April 2019; last patient last visit: 01 March 2021

### Pre-assignment

Screening details:

Main criteria for inclusion: Women, men and adolescents of  $\geq 12$  years of age; Diagnosis of "papulopustular acne" according to generally accepted criteria; On the face,  $\geq 25$  non-inflammatory lesions and  $\geq 20$  inflammatory lesions, thereof  $\leq 2$  nodular lesions; Investigator's Global Assessment (IGA) of acne severity grade 2, 3 or 4

### Period 1

Period 1 title	Treatment Period (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst

Blinding implementation details:

The tubes containing the study medications were neutral white. The attached labels were identical for all three preparations. All three study medications were indistinguishable with respect to visual or odorous characteristics. The random code was transferred to the data base not before the following actions were completed: data base closure, finalisation of the statistical analysis plan, a Blind Data Review and a subsequent Blind Data Report.

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	ClinBPO 30

Arm description:

Test product

Arm type	Experimental
Investigational medicinal product name	Clindamycin/Benzoyl Peroxide Gel (10 mg/g + 30 mg/g)
Investigational medicinal product code	D10AF51
Other name	
Pharmaceutical forms	Gel
Routes of administration	Cutaneous use

Dosage and administration details:

A thin layer of gel should be applied to the affected area once a day. The treatment area was defined as the acne affected areas on the face whereas face was considered as the area bounded by ears, hairline and lower margin of the mandibles. Contact with the mouth, eyes, lips, other mucous membranes or areas of irritated or broken skin should be avoided.

<b>Arm title</b>	Duac (10 mg/g + 30 mg/g)
------------------	--------------------------

Arm description:

Reference Product

Arm type	Active comparator
Investigational medicinal product name	Duac (10 mg/g + 30 mg/g)
Investigational medicinal product code	D10AF51
Other name	
Pharmaceutical forms	Gel
Routes of administration	Cutaneous use

Dosage and administration details:

A thin layer of gel should be applied to the affected area once a day. The treatment area was defined as the acne affected areas on the face whereas face was considered as the area bounded by ears, hairline and lower margin of the mandibles. Contact with the mouth, eyes, lips, other mucous membranes or

areas of irritated or broken skin should be avoided.

<b>Arm title</b>	Vehicle
Arm description: -	
Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	D10AF51
Other name	
Pharmaceutical forms	Gel
Routes of administration	Cutaneous use

**Dosage and administration details:**

A thin layer of gel should be applied to the affected area once a day. The treatment area was defined as the acne affected areas on the face whereas face was considered as the area bounded by ears, hairline and lower margin of the mandibles. Contact with the mouth, eyes, lips, other mucous membranes or areas of irritated or broken skin should be avoided.

<b>Number of subjects in period 1</b>	ClinBPO 30	Duac (10 mg/g + 30 mg/g)	Vehicle
Started	223	225	228
Completed	211	213	199
Not completed	12	12	29
Consent withdrawn by subject	1	3	1
Poor tolerability (patient)	3	1	1
Adverse event, non-fatal	2	2	2
Technical-logistic reasons	2	-	-
COVID-19 related	1	-	2
Lost to follow-up	1	-	1
Lack of efficacy	2	6	22

## Baseline characteristics

### Reporting groups

Reporting group title	Treatment Period
Reporting group description: -	

Reporting group values	Treatment Period	Total	
Number of subjects	676	676	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	378	378	
Adults (18-64 years)	298	298	
From 65-84 years	0	0	
85 years and over	0	0	
Gender categorical			
Units: Subjects			
Female	437	437	
Male	239	239	

### Subject analysis sets

Subject analysis set title	Safety data set
Subject analysis set type	Safety analysis

Subject analysis set description:

Comprises all randomised patients who had administered the study medication at least once and who provided at least one safety related outcome.

Subject analysis set title	FAS
Subject analysis set type	Full analysis

Subject analysis set description:

Consists of all patients as randomised who received study medication at least once and have a baseline assessment and at least one post-baseline assessment of the number of papulopustular acne lesions.

Subject analysis set title	PP
Subject analysis set type	Per protocol

Subject analysis set description:

Comprises all patients of the FAS who do not exhibit any major protocol violations.

Reporting group values	Safety data set	FAS	PP
Number of subjects	676	673	628
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0

Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	378	377	364
Adults (18-64 years)	298	296	264
From 65-84 years	0	0	0
85 years and over	0	0	0
Gender categorical			
Units: Subjects			
Female	437	435	394
Male	239	238	234

## End points

### End points reporting groups

Reporting group title	ClinBPO 30
Reporting group description:	
Test product	
Reporting group title	Duac (10 mg/g + 30 mg/g)
Reporting group description:	
Reference Product	
Reporting group title	Vehicle
Reporting group description: -	
Subject analysis set title	Safety data set
Subject analysis set type	Safety analysis
Subject analysis set description:	
Comprises all randomised patients who had administered the study medication at least once and who provided at least one safety related outcome.	
Subject analysis set title	FAS
Subject analysis set type	Full analysis
Subject analysis set description:	
Consists of all patients as randomised who received study medication at least once and have a baseline assessment and at least one post-baseline assessment of the number of papulopustular acne lesions.	
Subject analysis set title	PP
Subject analysis set type	Per protocol
Subject analysis set description:	
Comprises all patients of the FAS who do not exhibit any major protocol violations.	

### Primary: Treatment effect (inflammatory lesions)

End point title	Treatment effect (inflammatory lesions)
End point description:	
End point type	Primary
End point timeframe:	
Treatment start (Visit V1) to end-of-treatment (EOT) examination at Visit V8 (week 12).	

End point values	ClinBPO 30	Duac (10 mg/g + 30 mg/g)	Vehicle	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	207	213	227	
Units: percent change				
arithmetic mean (standard deviation)	82.7 (± 24.21)	83.7 (± 20.86)	51.5 (± 41.57)	

### Statistical analyses

Statistical analysis title	Analysis of efficacy
Statistical analysis description:	
The first part of the primary objective of this study was to show therapeutic equivalence of the test	



preparation ClinBPO 30 as compared to the reference DUAC. Therapeutic equivalence was statistically proven if the two-sided 95% confidence interval (CI) for  $\mu$  INFL-ClinBPO -  $\mu$  INFL-DUAC was completely contained within [-10.0, 10.0].

Comparison groups	ClinBPO 30 v Duac (10 mg/g + 30 mg/g)
Number of subjects included in analysis	420
Analysis specification	Pre-specified
Analysis type	equivalence
Parameter estimate	Mean difference (final values)
Point estimate	-1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.38
upper limit	3.3

<b>Statistical analysis title</b>	Superiority of Test over Vehicle
-----------------------------------	----------------------------------

Statistical analysis description:

In order to verify assay sensitivity of the study design, superiority of the two active preparations over vehicle was tested by means of two-sided significance tests with  $\alpha = 0.05$ . The primary test of superiority was carried out for the ITT data set.

Comparison groups	ClinBPO 30 v Vehicle
Number of subjects included in analysis	434
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	t-test, 2-sided

<b>Statistical analysis title</b>	Superiority of Reference over Vehicle
-----------------------------------	---------------------------------------

Statistical analysis description:

In order to verify assay sensitivity of the study design, superiority of the two active preparations over vehicle was tested by means of two-sided significance tests with  $\alpha = 0.05$ . The primary test of superiority was carried out for the ITT data set.

Comparison groups	Vehicle v Duac (10 mg/g + 30 mg/g)
Number of subjects included in analysis	440
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	t-test, 2-sided

### Primary: Treatment effect (total number of lesions)

End point title	Treatment effect (total number of lesions)
-----------------	--

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Treatment start (Visit V1) to end-of-treatment (EOT) examination at Visit V8 (week 12).

End point values	ClinBPO 30	Duac (10 mg/g + 30 mg/g)	Vehicle	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	207	213	227	
Units: percentage change				
arithmetic mean (standard deviation)	75.1 (± 23.27)	75.9 (± 22.55)	43.7 (± 36.84)	

## Statistical analyses

Statistical analysis title	Analysis of efficacy
----------------------------	----------------------

Statistical analysis description:

The first part of the primary objective of this study was to show therapeutic equivalence of the test preparation ClinBPO 30 as compared to the reference DUAC. Therapeutic equivalence was statistically proven if the two-sided 95% confidence interval (CI) for  $\mu$  TOTAL-ClinBPO -  $\mu$  TOTAL-DUAC was completely contained within [-10.0, 10.0].

Comparison groups	ClinBPO 30 v Duac (10 mg/g + 30 mg/g)
Number of subjects included in analysis	420
Analysis specification	Pre-specified
Analysis type	equivalence
Parameter estimate	Mean difference (final values)
Point estimate	-0.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.23
upper limit	3.56

Statistical analysis title	Superiority of Test over Vehicle
----------------------------	----------------------------------

Statistical analysis description:

In order to verify assay sensitivity of the study design, superiority of the two active preparations over vehicle was tested by means of two-sided significance tests with  $\alpha = 0.05$ . The primary test of superiority was carried out for the ITT data set.

Comparison groups	ClinBPO 30 v Vehicle
Number of subjects included in analysis	434
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	t-test, 2-sided

Statistical analysis title	Superiority of Reference over Vehicle
----------------------------	---------------------------------------

---

**Statistical analysis description:**

In order to verify assay sensitivity of the study design, superiority of the two active preparations over vehicle was tested by means of two-sided significance tests with  $\alpha = 0.05$ . The primary test of superiority was carried out for the ITT data set.

Comparison groups	Vehicle v Duac (10 mg/g + 30 mg/g)
Number of subjects included in analysis	440
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	t-test, 2-sided

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From inclusion visit (day 0, Visit V1) to end-of-treatment (EOT) examination at Visit V8 (week 12).

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	24.0
--------------------	------

### Reporting groups

Reporting group title	ClinBPO 30
-----------------------	------------

Reporting group description:

Test product

Reporting group title	Duac (10 mg/g + 30 mg/g)
-----------------------	--------------------------

Reporting group description:

Reference Product

Reporting group title	Vehicle
-----------------------	---------

Reporting group description: -

Serious adverse events	ClinBPO 30	Duac (10 mg/g + 30 mg/g)	Vehicle
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 223 (0.00%)	1 / 224 (0.45%)	0 / 228 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Infections and infestations			
Complicated appendicitis			
subjects affected / exposed	0 / 223 (0.00%)	1 / 224 (0.45%)	0 / 228 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 0.05 %

Non-serious adverse events	ClinBPO 30	Duac (10 mg/g + 30 mg/g)	Vehicle
Total subjects affected by non-serious adverse events			
subjects affected / exposed	55 / 223 (24.66%)	62 / 224 (27.68%)	46 / 228 (20.18%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Gastroenteropancreatic neuroendocrine tumour disease			

subjects affected / exposed occurrences (all)	0 / 223 (0.00%) 0	1 / 224 (0.45%) 1	0 / 228 (0.00%) 0
Melanocytic naevus subjects affected / exposed occurrences (all)	0 / 223 (0.00%) 0	1 / 224 (0.45%) 1	0 / 228 (0.00%) 0
Skin papilloma subjects affected / exposed occurrences (all)	0 / 223 (0.00%) 0	1 / 224 (0.45%) 1	0 / 228 (0.00%) 0
Pregnancy, puerperium and perinatal conditions Pregnancy subjects affected / exposed occurrences (all)	0 / 223 (0.00%) 0	0 / 224 (0.00%) 0	1 / 228 (0.44%) 1
General disorders and administration site conditions Application site dermatitis subjects affected / exposed occurrences (all)	2 / 223 (0.90%) 2	1 / 224 (0.45%) 1	1 / 228 (0.44%) 1
Application site dryness subjects affected / exposed occurrences (all)	12 / 223 (5.38%) 12	15 / 224 (6.70%) 15	5 / 228 (2.19%) 5
Application site erythema subjects affected / exposed occurrences (all)	9 / 223 (4.04%) 9	9 / 224 (4.02%) 9	4 / 228 (1.75%) 4
Application site exfoliation subjects affected / exposed occurrences (all)	3 / 223 (1.35%) 3	2 / 224 (0.89%) 2	0 / 228 (0.00%) 0
Application site hypersensitivity subjects affected / exposed occurrences (all)	2 / 223 (0.90%) 2	3 / 224 (1.34%) 3	1 / 228 (0.44%) 1
Application site irritation subjects affected / exposed occurrences (all)	0 / 223 (0.00%) 0	1 / 224 (0.45%) 1	0 / 228 (0.00%) 0
Application site pain subjects affected / exposed occurrences (all)	6 / 223 (2.69%) 6	7 / 224 (3.13%) 7	6 / 228 (2.63%) 6
Application site plaque			

subjects affected / exposed occurrences (all)	0 / 223 (0.00%) 0	0 / 224 (0.00%) 0	1 / 228 (0.44%) 1
Application site pruritus subjects affected / exposed occurrences (all)	2 / 223 (0.90%) 3	3 / 224 (1.34%) 3	1 / 228 (0.44%) 1
Application site scab subjects affected / exposed occurrences (all)	1 / 223 (0.45%) 1	0 / 224 (0.00%) 0	0 / 228 (0.00%) 0
Pyrexia subjects affected / exposed occurrences (all)	1 / 223 (0.45%) 1	1 / 224 (0.45%) 1	0 / 228 (0.00%) 0
Immune system disorders Milk allergy subjects affected / exposed occurrences (all)	0 / 223 (0.00%) 0	0 / 224 (0.00%) 0	1 / 228 (0.44%) 1
Reproductive system and breast disorders Dysmenorrhoea subjects affected / exposed occurrences (all)	1 / 223 (0.45%) 1	0 / 224 (0.00%) 0	2 / 228 (0.88%) 2
Polycystic ovaries subjects affected / exposed occurrences (all)	0 / 223 (0.00%) 0	0 / 224 (0.00%) 0	1 / 228 (0.44%) 1
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	5 / 223 (2.24%) 5	2 / 224 (0.89%) 2	1 / 228 (0.44%) 1
Rhinorrhoea subjects affected / exposed occurrences (all)	0 / 223 (0.00%) 0	1 / 224 (0.45%) 1	0 / 228 (0.00%) 0
Psychiatric disorders Sleep disorder subjects affected / exposed occurrences (all)	1 / 223 (0.45%) 1	0 / 224 (0.00%) 0	0 / 228 (0.00%) 0
Investigations Arthroscopy			

subjects affected / exposed occurrences (all)	0 / 223 (0.00%) 0	1 / 224 (0.45%) 1	0 / 228 (0.00%) 0
Injury, poisoning and procedural complications Joint injury subjects affected / exposed occurrences (all)	1 / 223 (0.45%) 1	1 / 224 (0.45%) 1	0 / 228 (0.00%) 0
Nervous system disorders Headache subjects affected / exposed occurrences (all)  Migraine subjects affected / exposed occurrences (all)	3 / 223 (1.35%) 4  1 / 223 (0.45%) 1	3 / 224 (1.34%) 4  0 / 224 (0.00%) 0	2 / 228 (0.88%) 2  0 / 228 (0.00%) 0
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	1 / 223 (0.45%) 1	0 / 224 (0.00%) 0	0 / 228 (0.00%) 0
Ear and labyrinth disorders Motion sickness subjects affected / exposed occurrences (all)	1 / 223 (0.45%) 1	0 / 224 (0.00%) 0	0 / 228 (0.00%) 0
Gastrointestinal disorders Abdominal pain subjects affected / exposed occurrences (all)  Diarrhoea subjects affected / exposed occurrences (all)  Dyspepsia subjects affected / exposed occurrences (all)  Gastrooesophageal reflux disease subjects affected / exposed occurrences (all)  Lip dry	1 / 223 (0.45%) 1  0 / 223 (0.00%) 0  0 / 223 (0.00%) 0  1 / 223 (0.45%) 1	0 / 224 (0.00%) 0  1 / 224 (0.45%) 1  0 / 224 (0.00%) 0  0 / 224 (0.00%) 0	1 / 228 (0.44%) 1  0 / 228 (0.00%) 0  1 / 228 (0.44%) 1  0 / 228 (0.00%) 0

subjects affected / exposed occurrences (all)	0 / 223 (0.00%) 0	1 / 224 (0.45%) 1	0 / 228 (0.00%) 0
Tooth malformation subjects affected / exposed occurrences (all)	1 / 223 (0.45%) 1	1 / 224 (0.45%) 1	0 / 228 (0.00%) 0
Toothache subjects affected / exposed occurrences (all)	1 / 223 (0.45%) 1	0 / 224 (0.00%) 0	0 / 228 (0.00%) 0
Skin and subcutaneous tissue disorders			
Acne subjects affected / exposed occurrences (all)	1 / 223 (0.45%) 1	0 / 224 (0.00%) 0	0 / 228 (0.00%) 0
Dermatitis allergic subjects affected / exposed occurrences (all)	1 / 223 (0.45%) 1	0 / 224 (0.00%) 0	0 / 228 (0.00%) 0
Dermatitis contact subjects affected / exposed occurrences (all)	1 / 223 (0.45%) 1	1 / 224 (0.45%) 1	0 / 228 (0.00%) 0
Dry skin subjects affected / exposed occurrences (all)	1 / 223 (0.45%) 1	1 / 224 (0.45%) 1	0 / 228 (0.00%) 0
Erythema subjects affected / exposed occurrences (all)	3 / 223 (1.35%) 3	1 / 224 (0.45%) 1	1 / 228 (0.44%) 1
Hand dermatitis subjects affected / exposed occurrences (all)	2 / 223 (0.90%) 2	0 / 224 (0.00%) 0	0 / 228 (0.00%) 0
Perioral dermatitis subjects affected / exposed occurrences (all)	0 / 223 (0.00%) 0	0 / 224 (0.00%) 0	1 / 228 (0.44%) 1
Photosensitivity reaction subjects affected / exposed occurrences (all)	0 / 223 (0.00%) 0	0 / 224 (0.00%) 0	1 / 228 (0.44%) 1
Pruritus subjects affected / exposed occurrences (all)	0 / 223 (0.00%) 0	1 / 224 (0.45%) 1	0 / 228 (0.00%) 0



Skin exfoliation subjects affected / exposed occurrences (all)	0 / 223 (0.00%) 0	1 / 224 (0.45%) 1	0 / 228 (0.00%) 0
Solar dermatitis subjects affected / exposed occurrences (all)	0 / 223 (0.00%) 0	1 / 224 (0.45%) 1	0 / 228 (0.00%) 0
Renal and urinary disorders Urinary tract discomfort subjects affected / exposed occurrences (all)	0 / 223 (0.00%) 0	0 / 224 (0.00%) 0	1 / 228 (0.44%) 1
Musculoskeletal and connective tissue disorders Back pain subjects affected / exposed occurrences (all)	0 / 223 (0.00%) 0	1 / 224 (0.45%) 1	0 / 228 (0.00%) 0
Myalgia subjects affected / exposed occurrences (all)	0 / 223 (0.00%) 0	1 / 224 (0.45%) 1	0 / 228 (0.00%) 0
Infections and infestations Body tinea subjects affected / exposed occurrences (all)	0 / 223 (0.00%) 0	1 / 224 (0.45%) 1	0 / 228 (0.00%) 0
Bronchitis subjects affected / exposed occurrences (all)	0 / 223 (0.00%) 0	3 / 224 (1.34%) 3	3 / 228 (1.32%) 3
COVID-19 subjects affected / exposed occurrences (all)	0 / 223 (0.00%) 0	1 / 224 (0.45%) 1	2 / 228 (0.88%) 2
Cystitis subjects affected / exposed occurrences (all)	1 / 223 (0.45%) 1	0 / 224 (0.00%) 0	0 / 228 (0.00%) 0
Furuncle subjects affected / exposed occurrences (all)	0 / 223 (0.00%) 0	1 / 224 (0.45%) 1	0 / 228 (0.00%) 0
Gastrointestinal viral infection subjects affected / exposed occurrences (all)	0 / 223 (0.00%) 0	0 / 224 (0.00%) 0	1 / 228 (0.44%) 1

Genital herpes			
subjects affected / exposed	0 / 223 (0.00%)	1 / 224 (0.45%)	0 / 228 (0.00%)
occurrences (all)	0	2	0
Hordeolum			
subjects affected / exposed	0 / 223 (0.00%)	0 / 224 (0.00%)	1 / 228 (0.44%)
occurrences (all)	0	0	1
Impetigo			
subjects affected / exposed	0 / 223 (0.00%)	1 / 224 (0.45%)	0 / 228 (0.00%)
occurrences (all)	0	1	0
Nasopharyngitis			
subjects affected / exposed	4 / 223 (1.79%)	3 / 224 (1.34%)	1 / 228 (0.44%)
occurrences (all)	4	3	1
Oral herpes			
subjects affected / exposed	2 / 223 (0.90%)	1 / 224 (0.45%)	1 / 228 (0.44%)
occurrences (all)	3	1	1
Pharyngitis			
subjects affected / exposed	1 / 223 (0.45%)	1 / 224 (0.45%)	1 / 228 (0.44%)
occurrences (all)	1	1	1
Pulpitis dental			
subjects affected / exposed	0 / 223 (0.00%)	0 / 224 (0.00%)	1 / 228 (0.44%)
occurrences (all)	0	0	1
Rhinitis			
subjects affected / exposed	2 / 223 (0.90%)	1 / 224 (0.45%)	2 / 228 (0.88%)
occurrences (all)	2	1	2
Upper respiratory tract infection			
subjects affected / exposed	3 / 223 (1.35%)	5 / 224 (2.23%)	6 / 228 (2.63%)
occurrences (all)	5	5	7
Urinary tract infection			
subjects affected / exposed	0 / 223 (0.00%)	2 / 224 (0.89%)	0 / 228 (0.00%)
occurrences (all)	0	2	0
Viral infection			
subjects affected / exposed	2 / 223 (0.90%)	1 / 224 (0.45%)	1 / 228 (0.44%)
occurrences (all)	3	1	1

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

None reported
---------------

Notes: